Vitiligo - Vîtilîgo
☆ AI Dermatology — Free Service
Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Tedawiya vîtîligoya tiliyan ji deverên din dijwartir e. Ji bilî ku ji hêla kozmetîkî ve nebaş e, vitiligo normal e û ne vegirtî ye. Di dermatolojiyê de, tedawiya herî bi bandor fototerapî an jî tedawiya lazerê (excimer) 2‑3 caran di hefteyê de, û herî kêm 1 sal e. Heke hûn ji ber sedemên aborî an ji ber ku hûn mijûl in nikaribin pir caran biçin nexweşxaneyê, hûn dikarin makîneyek fototerapî ya ku ji bo bikaranîna li malê hatî pejirandin biceribînin.
Vitiligo ya çavan
Vitiligo li destê
relevance score : -100.0%
ReferencesVitiligo nexweşiyek çermê ya gelemperî ye ku ji ber windabûna melanocytes dibe sedema çermên spî. Lêkolînên dawî nîşan dide ku ew nexweşiyek otoîmmune ye. Heger ew pir caran wekî pirsgirêkek kozmetîkî tê dîtin, dikare bi kûrahî bandorê li ser başbûna giyanî û jiyana rojane bibe. Di sala 2011-an de, pispor celebek bi navê segmental vitiligo ji yên din cuda dabeş kirin.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Nexweşên vitiligo yên çalak gelek vebijarkên dermankirinê hene, wek glucocorticoids pergalî, fototerapî, û immunosuppressants pergalî. Nexweşên vitiligo yên stabîl dibe ku ji kortikosteroidên herêmî, înhîbîtorên calcineurin‑ê yên herêmî, fototerapî, û prosedurên veguheztinê rehetiyê bibînin. Pêşveçûnên dawî yên di têgihîştina pêvajoyên bingehîn ên vitiligo de, rê li pêşkeftina dermanên armanckirî girtiye. Heya nuha, înhîbîtorên JAK‑ê yên herî sozdar in, ku tolerans û encamên fonksiyonel ên baş peyda dikin, tevî xetereya çalakkirina enfeksiyonên nepenî û bandorên aliyî yên pergalî yên ku bi ajanên din ên immunosuppressive re hevpar in. Lêkolîna domdar armanc dike ku cytokinesên sereke yên ku di pêşkeftina vitiligo de beşdar in nas bikin (IFN‑γ, CXCL10, CXCR3, HSP70i, IL‑15, IL‑17/23, TNF). Astengkirina van cytokines di modelên heywanan û di hin nexweşan de têkildar dibe. Wekî din, lêpirsînên li ser miRNA‑based therapeutics û adoptive Treg cell therapy jî têne kirin.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ji bo vîtîligoyê dermanek taybet nayê zanîn. Ji bo kesên ku çermê sivik, tav û makyaj hene, bi gelemperî têne pêşniyar kirin. Vebijarkên din ên dermankirinê dikarin kremên steroîdan an fototerapî bin.
○ Dermankirin
#Phototherapy
#Excimer laser
#Tacrolimus ointment